[The diagnostic value of serum KL-6 in connective tissue disease associated interstitial lung disease]

X Wu1, L J Wu, C N Luo

  • 1Department of Rheumatology and Immunology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001.

Zhonghua Yi Xue Za Zhi
|November 7, 2019
PubMed

Insights

Serum Krebs von den Lungen-6 (KL-6) is a valuable biomarker for diagnosing interstitial lung disease in connective tissue diseases (CTD-ILD). Elevated KL-6 levels indicate a higher risk of developing CTD-ILD.

Area of Science:

  • Rheumatology
  • Pulmonology
  • Clinical Diagnostics

Background:

  • Connective tissue diseases (CTD) can lead to interstitial lung disease (ILD), a serious complication.
  • Accurate and early diagnosis of CTD-ILD is crucial for effective management.
  • Serum biomarkers can aid in the early detection of CTD-ILD.

Purpose of the Study:

  • To assess the diagnostic utility of serum Krebs von den Lungen-6 (KL-6) for CTD-ILD.
  • To determine the correlation between KL-6 levels and the presence of CTD-ILD.

Main Methods:

  • A case-control study involving 84 patients with CTD-ILD and 91 patients with CTD without ILD.
  • Serum KL-6 levels were measured using enzyme-linked immunosorbent assay (ELISA).
  • Logistic regression analysis was employed to identify independent risk factors.

Main Results:

  • Serum KL-6 levels were significantly higher in the CTD-ILD group compared to the CTD group (P<0.001).
  • An optimal KL-6 cutoff value of 402 U/ml demonstrated 82.1% sensitivity and 86.8% specificity for CTD-ILD diagnosis (AUC=0.905).
  • Elevated KL-6 and decreased diffusing capacity of the lungs for carbon monoxide (DLcoSB%) were independent risk factors for CTD-ILD.

Conclusions:

  • Serum KL-6 is a significant biomarker for diagnosing CTD-ILD.
  • Increased KL-6 levels warrant attention for potential ILD development in CTD patients.
  • KL-6, alongside DLcoSB%, aids in identifying individuals at risk for CTD-ILD.